Logo for: PursueCare

PursueCare Speaks at DEA Telemedicine Listening Session

Several months ago, more than 38,000 public comments were submitted to the DEA regarding the proposed regulatory changes to telemedicine. As a result, the DEA held a Telemedicine Listening Session last week. We are honored to have been chosen as one of the 29 in-person presenters. Our Chief Medical Officer, James Ulager, MD, spoke on our behalf, discussing his and PursueCare’s perspective and experience working with patients within a virtual SUD clinic over the past three years.

We sincerely hope our participation will help inform the DEA’s decisions regarding future regulations on prescribing controlled substances via telemedicine, ensuring the treatment needs of people with substance use disorder (SUD) are met.